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Cooperative Induction of a Tolerogenic Dendritic Cell
Phenotype by Cytokines Secreted by Pancreatic Carcinoma
Cells1
Graziella Bellone,2* Anna Carbone,*‡ Carlo Smirne,* Tiziana Scirelli,* Alessandra Buffolino,*
Anna Novarino,§ Alessandra Stacchini,¶ Oscar Bertetto,§ Giorgio Palestro,† Claudio Sorio,!
Aldo Scarpa,! Giorgio Emanuelli,*‡ and Ulrich Rodeck#
Ag presentation by dendritic cells (DC) is essential to effective antitumor T cell responses in cancer patients. Depending on their
origin, maturation state, and the ambient cytokine milieu, DC can differentiate into distinct subpopulations, which preferentially
either induce Th1 cell activation (CD11c!,CD123" myeloid DC (MDC)) or immunosuppressive T cell development
(CD11c",CD123! plasmacytoid DC (PDC)). The present study was undertaken to characterize the effects of pancreatic carcinoma
cell-derived cytokines on immature monocyte-derived DC (iMo-DC) in vitro and in vivo. Medium conditioned by human pan-
creatic carcinoma cells inhibited iMo-DC proliferation, expression of costimulatory molecules (CD80 and CD40) and of HLA-DR,
and functional activity as assessed by MLR and IL-12p70 production. iMo-DC generated from pancreatic carcinoma patients in
advanced stages of the disease similarly showed decreased levels of HLA-DR expression and reduced ability to stimulate MLR in
response to CD40L and IFN-#. Moreover, in tumor-patient peripheral blood, the ratio of MDC to PDC cells was lower than
in healthy controls due to reduced numbers of MDC CD11c! cells. Importantly, rather than a single cytokine, a combination of
tumor-derived cytokines was responsible for these effects; these were primarily TGF-$, IL-10, and IL-6, but not vascular endo-
thelial growth factor. In summary, we have identified an array of pancreatic carcinoma-derived cytokines that cooperatively affect
iMo-DC activation in a manner consistent with ineffective antitumor immune responses. The Journal of Immunology, 2006, 177:
0000–0000.
E xocrine pancreatic carcinoma is one of the deadliest epi-thelial cancers due to advanced stage at diagnosis, earlysystemic dissemination, and poor response to chemother-
apeutic intervention or radiation therapy. The dearth of conven-
tional therapeutic options has, in recent years, motivated the search
for immunotherapeutic approaches to pancreatic cancer including
the development of vaccines (for a review, see Ref. 1). Concur-
rently, local and systemic alterations of the effector T cell response
have been recognized in pancreatic cancer patients. For example,
pancreatic carcinoma cells produce the immunomodulatory cyto-
kines TGF-! and IL-10, which skew T cell cytokine production
patterns in favor of a Th2 immunophenotype both in vitro and in
vivo (2). Furthermore, PBMC derived from pancreatic carcinoma
patients display a Th2 cytokine expression pattern upon activation
with either anti-CD3 Ab or Staphylococcus aureus strain Cowan I
(3). It is likely that these effects limit the efficacy of vaccine strat-
egies to combat pancreatic cancer because Th2 responses have
been associated with less effective antitumor effects in patients (for
a review, see Ref. 4). In contrast to T cell effector responses, little
is known about the effects of cytokines produced by pancreatic
tumors on Ag recognition and presentation.
The present study was designed to assess the effects of tumor-
associated cytokines secreted by pancreatic cancer cells on den-
dritic cell (DC)3 maturation and function. DC are professional
APC of hemopoietic origin with potent effects on primary T cell
differentiation and activation, and are thus of central relevance to
antitumor immune responses and vaccine development (5, 6). Two
types of DC precursors have been identified in humans peripheral
blood: myeloid monocytes, which differentiate into immature my-
eloid DC (MDC) upon exposure to GM-CSF and to IL-4, and
plasmacytoid cells, which display features of the lymphoid lineage
and require IL-3 for their development into plasmacytoid DC
(PDC) (7, 8). Upon activation, mature MDC produce large
amounts of bioactive IL-12 and preferentially induce naive CD4!
T cells to differentiate into Th1 cells, whereas mature PDC pro-
duce low levels of IL-12 and induce the development of Th2 (9,
10) or immunosuppressive T cells (11). Furthermore, the func-
tional properties of DC are affected by their state of maturation
when encountering T cells. For example, repetitive stimulation of
alloreactive T cells with mature CD83! human monocyte-derived
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DC (Mo-DC) induces predominantly Th1 characteristics. By con-
trast, repetitive stimulation with immature CD83" DC favors the
emergence of nonproliferating, IL-10-producing T cells (12), the
human counterpart of a recently described population of immuno-
regulatory T cells involved in maintaining peripheral tolerance
(13–16).
In tumor-bearing mice, DC preferentially induce a Th2 pheno-
type (17) possibly due to the interference of tumor-derived PGE2,
IL-10, and TGF-! (18–20). In addition, tumor-derived vascular
endothelial growth factor (VEGF) and IL-6 have been implicated
in ineffective DC responses to tumor challenges (21–23). In the
present study, we report that human pancreatic carcinoma cells
produce and secrete an array of cytokines, including VEGF, IL-6,
IL-10, and TGF-!, that are expected to affect DC maturation and
function. The multiplicity of pancreatic carcinoma-derived cyto-
kines with potential effects on DC maturation and functionality led
us to characterize the combined effects and the relative contribu-
tions of individual tumor-derived cytokines to the prevalent PDC
phenotype induced by medium conditioned by pancreatic carci-
noma cells. We found that PDC-like development was primarily
due to tumor-derived IL-10 and TGF-! and, to a lesser extent, to
IL-6, whereas VEGF secreted by pancreatic tumor cells had only
marginal effects on DC function in this setting. We further dem-
onstrate that immature monocyte-derived DC (iMo-DC) obtained
by incubation with medium conditioned by pancreatic carcinoma
cells induced a prevalent Th2 phenotype in PBL derived from
normal donors. These in vitro results mirror the situation in pan-
creatic carcinoma patients with advanced disease, who also display
a predominant PDC-like/Th2 phenotype. Finally, elevated plasma
levels of circulating IL-6, IL-10, and TGF-! have been observed in
these patients. Taken together, these results indicate that multiple
tumor-derived cytokines contribute to a systemic PDC-like phe-
notype in pancreatic carcinoma patients that is likely to hamper an
effective antitumor T cell response.
Materials and Methods
Cell lines, primary cell lines from xenograft and conditioned
medium (CM)
Human pancreatic carcinoma cell line PT-45 (provided by Dr. M. F.
DiRenzo, Department of Biomedical Sciences and Human Oncology, Uni-
versity of Turin, Turin, Italy), Capan-2, and BxPC-3 (American Type Cul-
ture Collection) were grown in DMEM supplemented with 10% FBS
(FCS). CM was obtained by seeding cells (1 # 105 cells/ml) in 5 ml of
fresh medium. After 48 h of incubation, supernatants were collected, cen-
trifuged to remove cells, and stored at "70°C.
Four early passage cell lines were established from pancreatic tumors
(#1 mucinous cystic carcinoma, stage T1N0; #2 anaplastic carcinoma,
stage T3N1a, #3 ductal carcinoma, stage T3N0, and #4 periampullar ade-
nocarcinoma, stage T3N0) which were resected and maintained as xeno-
grafts in immunodeficient mice. Cryopreserved samples of surgically re-
moved human tumor tissues, treated as described elsewhere (24), were
thawed quickly at 37°C and washed twice in RPMI 1640 before being
seeded on Matrigel. A minimum of three nu/nu mice were implanted s.c.
with two to five tissue fragments. When tumors developed, they were re-
moved from the mice under sterile conditions, finely minced, and trans-
ferred into 6-well cell culture dishes after resuspension in DMEM contain-
ing 10% FCS, 2 mM glutamine, 100 U of penicillin, and 0.1 mg/ml
streptomycin (Sigma-Aldrich). The cells were maintained at 37°C in a
humidified atmosphere with 5% CO2, and the medium was changed twice
weekly. Contaminating fibroblasts were removed by graded trypsinization,
and epithelial cell lineage of the remaining cells was verified by examining
cytocentrifuged cells for expression of epithelial markers using the follow-
ing mAbs: AE1-AE3, Ber-EP4, cytokeratin 7, and cytokeratins 8, 18, and
19 (clone 5D3) (DakoCytomation). When the purified epithelial cells
reached 80% confluence, the medium was removed, and cells were de-
tached and seeded at 1 # 105 cells/ml in fresh medium. CM of these
cultures were collected after 48 h, centrifuged to remove cells, and stored
until use at "70°C.
Tissue and patients
A group of 24 patients (16 males and 8 females, age range 36–81) with
confirmed primary pancreatic carcinomas were included in this study,
which was conducted under strict observance of the principles of the Dec-
laration of Helsinki. At the time of study, all patients were untreated. Sub-
sequently, 14 patients underwent surgical resection, and 10 patients with
locally advanced or metastatic tumors received palliative chemotherapy.
Pancreatic cancer tissue samples were frozen in liquid nitrogen immedi-
ately following surgical removal. Blood samples were drawn from patients
before surgery or treatment and from 24 normal age- and sex-matched
control donors. Sera were frozen at"70°C until used. For the experimental
use of the blood and surgical specimens, informed consent was obtained
from all patients and donors as per the hospital’s ethical guidelines.
Real-time RT-PCR
RNA extraction from established pancreatic carcinoma cell lines, xeno-
graft-derived primary cell lines, tissue specimens, and appropriate positive
controls consisting of PHA activated-normal PBMC and the human colon
carcinoma cell line DLD-1 was performed using TRIzol reagent (Invitro-
gen Life Technologies) following the manufacturer’s instructions. To re-
move traces of genomic DNA, total RNA (1 "g) was treated with DNase
I (Invitrogen Life Technologies) and reverse-transcribed to cDNA using
SuperScript II (Invitrogen Life Technologies) as described elsewhere (25).
Real-time quantitative RT-PCR analysis was performed on iCycler iQ sys-
tem (Bio-Rad) by SYBR green I dye detection as described elsewhere (2).
Amplification of !-actin, IL-6, IL-10, TGF-!1, TGF-!2, TGF-!3, and
VEGF transcripts was performed in duplicate in a PCR optical 96-well
reaction plate (Bio-Rad); 25 "l of the PCR mixture in each well contained
5 "l of cDNA (corresponding to 100 ng of total RNA), 2.5 "l of each
sequence-specific primer (150 nM for !-actin and 300 nM for others cy-
tokines), 12.5 "l of 1# iQ SYBR Green Supermix (Bio-Rad), and 2.5 "l
of nuclease-free water. The primer sequences listed in Table I were de-
signed to be cDNA specific and to work under equivalent reaction condi-
tions using Beacon Designer 2 Software (Bio-Rad); primers were synthe-
sized by Invitrogen Life Technologies and reconstituted in nuclease-free
water before use. A negative PCR control without cDNA template and a
positive control sample with a known cycle threshold value (Ct) were in-
cluded in each assay. Optimized thermal cycling conditions were as fol-
lows: 5 min at 95°C followed by 40 cycles of 15 s at 95°C and 1 min at
60°C (two-step PCR). Specificity of the PCR products was confirmed by
the melting curve program at the end of the reaction (55°C to 95°C with a
heating rate of 0.5°C/10 s and continuous fluorescence measurements).
PCR efficiency (E) was determined using the iCycler iQ software and the
method described by Ramakers et al. (26). For each sample, the
Ct was acquired using the Fit point method (27). The normalized gene
expression (NE) in cell lines was calculated by the following formula:
NE $ Ereference Ct reference/Etarget Ct target. The statistical significance of dif-
ferences in mRNA expression of the cytokine examined in patients and
control groups was analyzed using the Relative Expression Software Tool
for group-wise comparison and statistical analysis of relative expression
results in real-time PCR (28). This software calculates an expression ratio
relative to the control group (normal pancreas tissue) normalized to a ref-
erence gene (!-actin). The mRNA expression data for !-actin showed
no significant changes between control and patient groups. The
expression ratio (R) is R $ Etarget %Ct target (mean control " mean sample)/
Ereference %Ct reference (mean control " mean sample).
Immunohistochemistry
Consecutive paraffin wax-embedded tissue sections were subjected to im-
munostaining using peroxidase-based visualization DakoCytomation
LSAB kit (DakoCytomation), following the manufacturer’s recommenda-
tions. The primary Abs used for immunohistochemistry were as follows: an
anti- IL-6 goat antiserum (dilution 1/200; Santa Cruz Biotechnology), anti-
IL-10 rat mAbs (clones JES3-12G8) (dilution 1/1000; BD Pharmingen), an
anti-TGF-!1 rabbit antiserum (dilution 1/20; Santa Cruz Biotechnology),
an anti-TGF-!2 rabbit antiserum (dilution 1/40; Santa Cruz Biotechnol-
ogy), an anti-TGF-!3 rabbit antiserum (dilution 1/20; Santa Cruz Biotech-
nology), and an anti-VEGF rabbit antiserum (dilution 1/100; Santa Cruz
Biotechnology). Sections were subjected to heat-induced epitope retrieval
(Target Retrieval Solution; DakoCytomation) for 10 min at 100°C. Dia-
minobenzidine tetrahydrochloride was used as chromogen. The slides were
then counterstained with Mayer hematoxylin for 5 s, dehydrated, and
mounted in Clarion (Biomeda). To ensure Ab specificity, consecutive sec-
tions were incubated with isotype-matched control Igs and in the absence
of primary Ab. In these cases, no specific immunostaining was detected.
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Generation of immature DC from adherent peripheral blood
cells (iMo-DC)
Human monocytes were isolated from buffy coat PBMC using Ficoll-
Hypaque density gradient centrifugation, followed by a selection of cells
adherent to cell culture-treated plastic surfaces (1 # 107 PBMC/ml, 2 h).
DC were generated from adherent cells (1# 106 cells/ml) in 6-well culture
plates (Costar) in RPMI 1640 containing 10% heat-inactivated FCS and
penicillin/streptomycin supplemented with human rGM-CSF (100 ng/ml)
and IL-4 (10 ng/ml) (R&D Systems). The effects of pancreatic carcinoma-
derived secreted factors on iMo-DC generation were examined by the ad-
dition of 20% (v) medium conditioned by pancreatic carcinoma cells from
day 0 onward. In select experiments, CM were pretreated with neutralizing
Abs against TGF-! (pan-specific polyclonal rabbit Ab; R&D Systems),
IL-6 (polyclonal goat Ab; R&D Systems), IL-10 (rat mAb clone 12G; BD
Pharmingen), alone, or in combination or with appropriate irrelevant Abs
for the control.
Allogeneic T cell proliferation assay
iMo-DC cells were used in primary MLR to stimulate allogeneic responder
T cells isolated by negative immunomagnetic depletion of nonadherent
PBMC from healthy volunteers using a mAb mixture containing anti-
CD14, -CD19, -CD20, -CD16, and -CD36 (BD Pharmingen) and MACS
separation columns (Miltenyi Biotec). Graded numbers of irradiated (30
Gy) iMo-DC from normal subjects or patients were mixed with allogeneic
T cells (2 # 105/200 "l) in 96-well U-bottom culture plates in RPMI 1640
containing 10% heat-inactivated FCS. To determine DNA synthesis, cells
were pulsed with 0.5 "Ci of [3H]TdR (GBq/mM; DuPont-New England
Nuclear) for the last 5 h of a 5-day culture. Cellular DNA was collected on
glass fiber filters, and [3H]TdR incorporation was measured in a beta
counter. Results are expressed as mean cpm & SD in triplicates. To mea-
sure IFN-# production, 100 "l of supernatants was harvested and frozen at
"70°C.
FACS analysis
Double-staining immunofluorescence was performed by incubating cells
for 30 min at 4°C with appropriate concentration of the following Abs:
FITC-labeled anti-CD14, -CD1a, -CD83, and -CD86; and PE-labeled anti-
HLA-DR, -CD40 (BD Pharmingen), anti-CD80 (Serotec), and anti-CD95
(Caltag Laboratories). After washing, cells were analyzed by flow cytom-
etry. Results are expressed as the percentage of positive cells or as the
mean fluorescence intensity (MFI), which was calculated by subtracting the
autofluorescence of unstained cells from the fluorescence intensity of the
Ab-labeled cells. To detect CD11c!- and CD123!-expressing cells, FACS
analyses were performed by direct immunofluorescence using three-color
staining. PBMC were stained with lineage mAb mixture (LIN), consisting
of FITC-conjugated anti-CD3, -CD14, -CD16, -CD19, -CD20, and
-CD56 mixture; PerPC-labeled anti-HLA-DR; and PE-labeled anti-
CD11c or anti-CD123. mAbs and FITC-, PE-, and PerCP-conjugated
isotype control murine mAbs were obtained from BD Pharmingen.
FACS analyses were performed on a FACSCalibur flow cytometer (BD
Biosciences) equipped with filter settings for FITC (530 nm), PE (585
nm), and PerCP fluorochromes ('650 nm). Cells that were negative for
CD3, CD14, CD16, CD19, CD20, CD56 (LIN"), and HLA-DR! were
gated and analyzed for CD11c and CD123 expression. The incidence of
each subset was expressed as a percentage of lineage HLA-DR! PBMC.
In addition, the DC2:DC1 ratio was determined for each subject at the
time of sampling.
Apoptosis detection assay
iMo-DC were assessed for early apoptosis by evaluating phosphatidylser-
ine residues on the cell surface using Annexin VFITC (BioVision). Late-
stage apoptosis associated with compromised membrane permeability was
measured by propidium iodide (PI) staining (50 "g/ml in PBS). Annexin
VFITC binding was determined by flow cytometry (Coulter Epics IV Cy-
tometer; Beckman Coulter) (Ex $ 488 nm, Em $ 530 nm) using FITC
signal detector (FL1) and PI staining by the PE emission signal detector
(FL2). The results are based on a percentage of total gated cells (104 cells).
IL-12 and IL-10 release induction
iMo-DC cells were cultured in 96-well plates with or without human
CD40L- or CD32L-transfected fibroblasts in the presence or absence of
20% medium conditioned by pancreatic carcinoma cells. To measure IL-12
p70 and IL-10 production, 100 "l of supernatants were harvested after 48 h
of coincubation and frozen at "70°C until further analysis.
Determination of TGF-!, IL-10, IL-6, IFN-#, IL-12 p70, and
VEGF
Cytokine levels were measured using commercially available ELISA kits
following the manufacturer’s directions. Secreted IL-6, IL-10 (Euroclone)
TGF-!1, TGF-!2, and VEGF (R&D Systems) were determined in cell-free
CM from pancreatic carcinoma cell lines, peripheral was blood collected
from patients and from healthy age- and sex-matched donors, and IFN-#
(Bender MedSystems) was measured in supernatants from primary MLR,
IL-12 p70 (Amersham Biosciences), and IL-10 in supernatants from acti-
vated DC. The minimum detectable doses were below 0.8 pg/ml for IL-6,
5 pg/ml for IL-10, 7 pg/ml for TGF-!1 and TGF-!2, 9 pg/ml for VEGF,
3 pg/ml for IL-12p70, and 1.5 pg/ml for IFN-#. All samples were assayed
in duplicate.
Statistical analysis
The significance of the difference of means was analyzed using the Student
t test or the Mann-Whitney rank-sum test using SigmaPlot software (Jandel
Scientific Software).
Results
Patterns of cytokine mRNA and protein expression in pancreatic
carcinoma cells in situ and in vitro
Cytokine gene expression was quantitatively assessed in human
pancreatic carcinoma cell lines, as well as in primary cell lines,
tumors, and in control samples (normal pancreas) using real-time
Table I. Primer sequences for cytokine quantification by real-time RT-PCR
Primer Set
GenBank
Accession No. Primer Sequence (5(33()
RT-PCR
Ea (%)
!-actin NM_001101 FW: GCG AGA AGA TGA CCC AGA TC 96
RW: GGA TAG CAC AGC CTG GAT AG
IL-6 M54894 FW: GTG TTG CCT GCT GCC TTC 101.3
RW: AGT GCC TCT TTG CTG CTT TC
IL-10 M57627 FW: GAA CCA AGA CCC AGA CAT C- 98.4
RW: CAT TCT TCA CCT GCT CCA C-
TGF-!1 X02812 FW: GAC ACC AAC TAT TGC TTC AG 112.1
RW: CAG GCT CCA AAT GTA GGG
TGF-!2 M19154 FW: GCG AGA GGA GCG ACG AAG AG 98.8
RW: TGT AGA AAG TGG GCG GGA TGG
TGF-!3 J03241 FW: CGC CTC AAG AAG CAG AAG 115.3
RW: TGT CGG AAG TCA ATG TAG AG
VEGF NM_003376 FW: GCC TTG CCT TGC TGC TCT AC 100.6
RW: TGA TGA TTC TGC CCT CCT CCT TC
a E, efficiency deducted from the slope(s) of the standard curve based on E - eln 10/"s "1; FW, forward primer; RW, reverse
primer.
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RT-PCR. Normalized gene expression was compared across es-
tablished and primary cell lines (Fig. 1). All three pancreatic car-
cinoma cell lines included in this analysis (PT-45, Capan-2, and
BxPC-3) constitutively expressed comparable levels of TGF-!1
mRNA. By contrast, IL-6 expression was variable with PT-45 and
Capan-2 expressing low steady-state IL-6 transcripts compared
with BxPC-3. In addition, Capan-2 cells expressed high levels of
IL-10, TGF-!2, and TGF-!3 mRNA compared with the other two
cell lines. Conversely, PT-45 and BxPC-3 expressed high levels of
VEGF mRNA compared with Capan-2 cells (Fig. 1A). Relatively
high levels of IL-10, TGF-!2, and VEGF transcripts, intermediate
level of IL-6, very low levels of TGF-!1, and absence of TGF-!3
were detected in one primary cell line (#1). Comparatively high
levels of TGF-!2 (high), VEGF (low), and IL-10 (minimal)
mRNA were found in #2 and #3 cell lines. High, low, and minimal
mRNA expression for IL-6, TGF-!1, and TGF-!3 mRNA, respec-
tively, were detected in #2 cell line. The #4 cell line expressed
moderate levels of IL-6 and TGF-!2 mRNA and minimal levels of
IL-10 and TGF-!1. The #3 and #4 cell lines were found to be
negative for IL-6 and TGF-!1 messages and for TGF-!3 mRNA,
respectively (Fig. 1A).
Next, we determined steady-state mRNA levels for the cyto-
kines under investigation in pancreatic cancer in situ. Tumor tis-
sues were heterogeneous similar to the observations in pancreatic
cancer cell lines. High steady-state levels relative to normal pan-
creatic tissue were observed for TGF-!1 ( p $ 0.02), TGF-!2
( p $ 0.001), TGF-!3 ( p $ 0.001), IL-10 ( p $ 0.04), and
VEGF ( p $ 0.007) transcripts (Fig. 1B), whereas mRNA levels of
IL-6 ( p $ 0.06) were not significantly above normal.
We then used ELISA to examine cytokine concentrations in
medium conditioned by BxPC-3, Capan-2, and PT-45 pancreatic
carcinoma cells, in primary cell line supernatants (Fig. 2A), and in
sera from pancreatic carcinoma patients (n $ 24) and normal
healthy age- and sex-matched control donors (Table II). Whereas
BxPC-3 cells secreted considerable quantities of all cytokines un-
der investigation, Capan-2 and PT-45 cells secrete low amounts of
IL-6. PT-45 cells did not produce any IL-10. Release of IL-10,
TGF-!2, and VEGF was detected in the supernatants of all pri-
mary cell lines. Low levels of IL-6 were produced by #1, #2, and
#4 cells, whereas TGF-!1 was detected in #2 cell supernatant at
high level and in the other supernatants at low (#1) or minimal
levels (#3 and #4) (Fig. 2A).
FIGURE 1. Expression of IL-6, IL-10,
TGF-!, and VEGF mRNA transcripts in pancre-
atic carcinoma cell lines, primary pancreatic car-
cinoma cell lines and in pancreatic tumors in
situ. A, Cytokine mRNA levels in PT45, Ca-
pan-2, BxPC-3, #1, #2, and #3 cell lines were
assessed by real-time RT-PCR and normalized
to !-actin mRNA levels. Mean normalized gene
expression values are shown. B, Cytokine
mRNA expression in pancreatic tumors in situ.
Expression ratios were calculated as the median
in pancreatic carcinoma specimens in relation to
normal pancreatic tissue calculated using the
Relative Expression Software Tool. The hori-
zontal line represents the median. The box en-
compasses the 25th to 75th percentiles, and the
error bars show the 10th to 90th percentiles. F,
Outliers.
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Significantly higher levels of all cytokines under investigation
were detected in patients’ sera compared with controls (Table II).
In addition, patients with locally advanced or metastatic disease
had significantly higher serum levels of IL-6, IL-10, and TGF-!2
compared with patients at early disease stages.
Immunohistochemical analysis confirmed and extended these
results by demonstrating the presence of cytokines in tumor cells
in situ (Fig. 2B). Consistent with our earlier results (2), TGF-!1,
TGF-!2, TGF-!3, as well as VEGF (this study), immunoreactivity
was observed in all patient tumor specimens (14 of 14). Expression
Table II. Cytokine serum levels
Group
Serum Levels, Median (range) (pg/ml)
IL-6 IL-10 TGF-!1 TGF-!2 VEGF
Controls (n $ 3.95 (1–5.88) 7.53 (2.61–11.69) 24 (4.73–47.64) 393 (132.8–543.2) 101 (0–293)
Patients (n $ 24) 5.47 (1.8–10.15) 14.31 (5.7–25.5) 37.3 (6.6–55.02) 734.9 (163.7–1784.6) 211.5 (0–735)
pa 0.04 0.02 0.02 0.005 )0.001
Patients with early
disease stage
(n $ 14)
3.9 (1.8–10.1) 8.7 (5.7–18.7) 593.8 (163.7–945)
Patients with
advanced disease
(n $ 10)
6.1 (3.6–17.6) 19.4 (9.6–25.5) 916.4 (434.9–1784.6)
pb 0.03 )0.001 0.007
a Value of p vs controls.
b Value of p vs patients with early disease stage.
FIGURE 2. A, Concentration of IL-6, IL-10, TGF-
!1, TGF-!2, and VEGF in CM derived from PT-45,
Capan-2, and BxPC-3, #1, #2, #3, and #4 cells measured
by ELISA. The mean level of cytokines detected in du-
plicate CM samples are shown. B, Detection of IL-6,
IL-10, TGF-!1, TGF-!2, TGF-!3, and VEGF in pan-
creatic carcinomas in situ as determined by immunohis-
tochemistry. Specimens are representative examples of
14 tumor samples analyzed (original magnification,
#250). A representative negative control is also shown.
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of IL-6 and IL-10 was observed in 8 of 14 and 12 of 14 samples,
respectively.
Collectively, these results establish that, in vitro and in vivo,
pancreatic carcinoma cells are a source of multiple cytokines that
can be expected to affect DC maturation and functionality locally
at the tumor site and, potentially, systemically.
Cytokines secreted by pancreatic carcinoma cells inhibit DC
yield and alter the phenotype of DC derived from normal
monocytes
The concurrent production of IL-6, IL-10, TGF-!, and VEGF by
pancreatic carcinoma cells raised the issue of how these cytokines,
alone or in combination, affect DC cell function in pancreatic can-
cer patients. To address this issue, we first assessed the effects of
pancreatic carcinoma-derived CM on DC generated from normal
peripheral blood-derived adherent cells, cultured for 7 days in the
presence of GM-CSF and IL-4; under these conditions, large cells
appeared in control cultures, exhibiting DC morphology with mul-
tiple fine dendrites, which we refer to as iMo-DC from now on
(Fig. 3A), whereas in pancreatic carcinoma CM-treated DC cul-
tures, dendropoiesis was inhibited, especially in the presence of
Capan-2 and BxPC-3 CM. In addition, when medium conditioned
by either Capan-2 or BxPC-3 cells was added to the cultures dur-
ing the generation of iMo-DC, the DC cell yield (HLA-
DR!CD40!CD80!CD86! cells) was reduced significantly ( p $
0.01 and p $ 0.04, respectively) (Table III). By contrast, addition
of PT-45 CM had no effect on iMo-DC yield within the 7-day
observation period. The reduced iMo-DC yield upon exposure to
Capan-2 and BxPC-3 CM was associated with a marked increase
in cells undergoing apoptotic death ( p ) 0.001 and p $ 0.005,
respectively) as determined by binding of AnnexinFITC to cell sur-
face phosphatidylserine residues (Table III). A similar increase in
the number of apoptotic/dead cells as assessed by annexinV/PI
double staining was observed in iMo-DC populations exposed to
Capan-2 and BxPC-3 CM ( p $ 0.003 and p $ 0.04, respectively)
(Table III).
In addition to overall cell yield, pancreatic carcinoma-derived
supernatant also affected the phenotype of iMo-DC, determined by
monitoring expression of the surface Ags CD14, CD1a, CD40,
CD80, CD83, CD86, and HLA-DR 7 days after initiating DC cul-
tures. Compared with iMo-DC generated in the absence of CM
(Fig. 3, B and C), the addition of all pancreatic carcinoma cell line
CM increased both the frequency of Ag-positive cells and the Ag
density per cell of CD14 ( p $ 0.05) but reduced CD40 and
HLA-DR expression ( p $ 0.001). Capan-2 and BxPC-3 CM also
reduced the percentage of CD83! cells ( p $ 0.05). CD1a expres-
sion (frequency and density) was only affected by the addition of
Capan-2 CM ( p $ 0.05), whereas CD86 expression (frequency
and density) was not altered significantly by the addition of
pancreatic-carcinoma-derived CM.
Defective functional activity of iMo-DC generated in the
presence of medium conditioned by pancreatic carcinoma cells
The functional activity of DC cells depends, in part, on expression
of HLA-DR and costimulatory molecules (5). Reduced expression
of these cell surface receptors, as observed in the presence of pan-
creatic carcinoma cell-derived supernatants, may thus cause al-
tered functionality of Mo-DC. To test this hypothesis, we first
evaluated the capacity for immunostimulation by iMo-DC exposed
to pancreatic carcinoma cell CM in MLR assays using allogeneic
T cells (Fig. 4). Consistent with the hypothesis, iMo-DC generated
in the presence of any of the pancreatic carcinoma-derived CM,
but in particular of Capan-2 and BxPC-3 CM, displayed markedly
decreased allostimulatory activity compared with control DC at all
T cell ratios tested ( p $ 0.03) (Fig. 4A). Similarly, iMo-DC gen-
erated in the presence of supernatants of primary cell lines #1, #2,
and #3 displayed a significantly impaired immunostimulatory
function at all ratios tested ( p $ 0.006), while no reduced capacity
was observed in iMo-DC generated in the presence of #4 cell CM
(Fig. 4B).
IL-12 is a DC-derived factor that directs the development of Th1
cells, producing high levels of IFN-# (29, 30), whereas IL-10 lim-
its the ability of DC to initiate a Th1 response by interfering with
the up-regulation of costimulatory molecules and IL-12 production
(20). Therefore, we compared the effects of CM derived from PT-
45, Capan-2, or BxPC-3 and all four primary cell lines on the
capacity of Mo-DC to produce bioactive IL-12 (IL-12 p70) and
IL-10 when coactivated by CD40L and to induce IFN-# produc-
tion by allogeneic T cells. Stimulation for 24 h with a combination
of IFN-# and CD40L, but not CD32L (used as negative control),
resulted in significantly higher levels of IL-12 p70 production by
control DC cells compared with DC exposed to pancreatic carci-
noma-derived CM (Capan-2 CM 87 & 14 vs 367 & 54.3 pg/ml,
FIGURE 3. A, Effects of pancreatic carcinoma cell CM on iMo-DC
morphology. The results shown are representative of seven experiments. B,
Effects of pancreatic carcinoma cell CM on iMo-DC phenotypic profile.
Double-staining immunofluorescence with appropriate Abs was performed
on control iMo-DC and iMo-DC generated in the presence of pancreatic
carcinoma cell line CM collected on day 6 of culture and analyzed by
FACS. C, Surface marker expression of iDC in the presence and absence
of pancreatic carcinoma CM. The data shown represent mean percentage of
positive cells & SD (B) or MFI (C) of seven independent experiments. !,
p $ 0.05; !!, p $ 0.001 in relation to iMo-DC cultured in the absence of
cell line CM.
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p $ 0.004; BxPC-3 CM 103.9 & 23 vs 367 & 54.3 pg/ml, p $
0.007; and PT-45 CM 231.4 & 46.4 vs 367 & 54.3 pg/ml, p $
0.001) (Fig. 5A). Similarly, the CD40L/IFN-#-stimulated DC gen-
erated in the presence of CM derived from primary pancreatic
carcinoma cell lines released lower levels of IL-12p70 compared
with control DC (#1 CM 136 & 19 vs 799 & 87 pg/ml, p $ 0.002;
FIGURE 4. Effects of pancreatic carcinoma
CM on iMo-DC-induced stimulation of heter-
ologous T cells in MLR. A, iMo-DC were gen-
erated by culturing PB adherent cells from do-
nors (n $ 7) for 7 days in the presence of GM-
CSF and IL-4 in the presence or absence of
20% CM (v) derived from PT-45, Capan-2, or
BxPC-3 cells as indicated. Cells were then har-
vested, irradiated, and used to stimulate allo-
geneic T cells. T cell proliferation was deter-
mined using [3H]TdR uptake after 5 days of
culture. Results are expressed as mean & SD
of triplicate culture. B, iMo-DC were gener-
ated by culturing PB adherent cells from do-
nors (n $ 3) for 7 days in the presence of GM-
CSF and IL-4 in the presence or absence of
20% CM (v) derived from #1, #2, #3, and
#4 cells as indicated.!, p $ 0.05; !!, p $ 0.001
vs iMo-DC generated in the absence of
supernatants.
Table III. Effects of medium conditioned by pancreatic carcinoma cells on DC yield and apoptosis
Culture Conditions
iMo-DC Yield
(%)a
Percentage of Positive Cells
Annexin Vb Annexin V/PIc PId
Control 53 & 19.9e 10.8 & 3.5 5.2 & 0.5 4.6 & 1.5
PT-45 CM 43 & 17.3 12.1 & 2.5 5.6 & 1.3 5.8 & 1.2
pf NS NS NS NS
Capan-2 CM 19.5& 13 23.2& 2 14.8 & 1.4 9.5& 2
p 0.01 0.005 0.003 NS
BxPC-3 CM 24.8& 17.3 18.9& 3.2 12.8 & 2.3 7.9& 1.6
p 0.03 )0.001 0.04 NS
a Percentage of iMo-DC (HLA-DR!CD40!CD80!CD86! cells) based on starting population (1 # 106 adherent cells).
b Early apoptosis.
c Intermediate apoptosis.
d Late apoptosis.
e Mean percentage & SD of five separate experiments.
f vs control.
balt6/zim-jimm/zim-jimm/zim01706/zim3687-06a eideg S%6 6/30/06 15:07 Art: 3687 Input-mw
7The Journal of Immunology
F5
#2 CM 126.5& 34 vs 799& 87 pg/ml, p $ 0.001; #3 CM 187.8&
21 vs 799 & 87 pg/ml, p $ 0.001; and #4 CM 257.7 & 34 vs
799 & 87 pg/ml, p $ 0.002) (Fig. 5B).
In marked contrast, IL-10 levels showed the opposite pattern in
that iMo-DC generated in the presence of pancreatic carcinoma
cell CM produced significantly higher levels of this cytokine than
control activated Mo-DC (Capan-2 CM 673 & 105 vs 237 & 81
pg/ml, p $ 0.001; BxPC-3 CM 453.2 & 120 vs 237 & 81 pg/ml,
p $ 0.01; PT-45 CM 341.5& 52 vs 237& 81 pg/ml, p $ 0.02; #1
CM 804.8 & 183 vs 424.9 & 58 pg/ml, p $ 0.034; #2 CM 699 &
125 vs 424.9 & 58 pg/ml, p $ 0.019; #3 CM 742.7 & 149 vs
424.9 & 58 pg/ml, p $ 0.026; and #4 CM 638 & 85 vs 424.9 &
58 pg/ml, p $ 0.005) (Fig. 6, A and B). Since IFN-# is considered
to play a key role in determining cell-mediated immune responses
leading to the eradication of tumor cells (31), we next assessed
whether control iMo-DC and iMo-DC generated in the presence of
cell line supernatants differed in their ability to induce IFN-# pro-
duction by allogeneic T cells. As shown in Fig. 7, A and B, control
iMo-DC induced significantly higher IFN-# production by T cells
compared with iMo-DC generated in the presence of Capan-2 or
BxPC-3 CM (1025.8 & 234 pg/ml vs Capan-2 CM 432.3 & 98.1
pg/ml, p $ 0.02, and vs BxPC-3 CM 575.9 & 56 pg/ml, p $ 0.04)
or primary cell line CM (2182.7 & 314 pg/ml vs #1 CM 1533 &
102 pg/ml, p $ 0.001; #2 CM 1296.2 & 121 pg/ml, p $ 0.001; #3
CM 1259.5& 89 pg/ml, p $ 0.001; and #4 CM 1720& 231 pg/ml,
p $ 0.009).
Collectively, these results indicate that pancreatic carcinoma
cell-derived supernatants markedly impair immunostimulatory
function and the induction of allogeneic Th1 responses by
iMo-DC.
Effects of individual pancreatic carcinoma-derived cytokines on
DC generation
To further assess the relative contribution of specific pancreatic
carcinoma-derived cytokines to DC functional impairment, we
used neutralizing Abs known to inhibit the biological activity of
either TGF-! or IL-10 or IL-6 or VEGF. CM were pretreated for
1 h with the appropriate neutralizing Abs either alone or in com-
bination before addition to iMo-DC in the presence of GM-CSF
and IL-4. Fig. 8A illustrates that neutralizing Abs to IL-6, IL-10,
and TGF-! independently reversed the effects of pancreatic carci-
noma-derived CM on allostimulatory capacity as assessed by
MLR, although to different degrees. A neutralizing Ab to VEGF
had negligible effect on immunostimulatory function. By contrast,
a combination of IL-6-, IL-10-, TGF-!-, and VEGF-specific neu-
tralizing Abs completely reversed the allostimulatory capacity-in-
hibitory activity produced by all pancreatic carcinoma cell lines. In
fact, in the presence of the Ab mixture, iMo-DC exposed to CM
displayed higher or similar allostimulatory activity to that of con-
trol iMo-DC (PT-45 CM, 112% of control [3H]TdR uptake; Ca-
pan-2 CM, 100% of control [3H]TdR uptake; and BxPC-3 CM,
98% of control [3H]TdR uptake) (Fig. 8B). As shown in Table IV,
FIGURE 5. Effects of pancreatic carcinoma CM on IL-12 p70 produc-
tion by DC. Normal DC, generated in the presence or absence of 20% of
pancreatic carcinoma CM, were cotreated with CD40L and IFN-# (100
ng/ml) for 24 h, and the levels of IL-12 heterodimer (p70) were measured
by specific ELISA. CD32L was used as negative control. A, DC generated
in the presence of CM derived from PT-45, Capan-2, or BxPC-3 cells. B,
DC generated in the presence of CM derived from #1, #2, #3, and #4 cells.
!!, p $ 0.001; !!!, p ) 0.0001 vs DC generated in the absence of super-
natants. All values are expressed as mean& SD pg/ml of five (A) and three
(B) independent experiments.
FIGURE 6. Effects of pancreatic carcinoma-derived CM on IL-10 pro-
duction by DC. Normal DC, generated in the presence or absence of 20%
of pancreatic carcinoma CM, were cotreated with CD40L and IFN-# (100
ng/ml) for 24 h, and the levels of IL-10 were measured by specific ELISA.
CD32L was used as negative control. A, DC generated in the presence of
CM derived from PT-45, Capan-2, or BxPC-3 cells. B, DC generated in the
presence of CM derived from #1, #2, #3, and #4 cells. !!, p $ 0.001; !!!,
p ) 0.0001 vs DC generated in the absence of supernatants. All values are
expressed as mean & SD pg/ml of five (A) and three (B) independent
experiments.
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the recovery of allostimulatory activity by iMo-DC generated in
the presence of pancreatic carcinoma CM pretreated with the com-
bination of neutralizing Abs is associated with an increased ex-
pression of surface molecules with costimulatory and recognition
properties such as CD40 and HLA-DR, strengthening the concept
of the immunomodulatory capacity of the tumor-derived
cytokines.
DC generated ex vivo from pancreatic carcinoma patients
To address the question whether elevated circulating TGF-!, IL-6,
and IL-10 levels in pancreatic carcinoma patients may similarly
affect Mo-DC differentiation and function in vivo, we generated
iMo-DC from patients’ PBMC before either surgery or chemother-
apeutic treatment by culturing adherent cells for 7 days in the
presence of GM-CSF and IL-4. The yields of adherent cells in
patients were comparable to those in controls (mean, 14.3 and
16.5%, respectively). Immunophenotypic analyses, performed on
iMo-DC generated ex vivo from adherent cells, showed no signif-
icant differences between tumor patients and normal donors, in
either frequency or density per cell, for all Ags. However, when
this analysis was restricted to patients with advanced disease, the
frequencies of CD40, CD80, and HLA-DR-positive DC were sig-
nificantly lower ( p $ 0.03), and the frequency of CD14 was higher
( p $ 0.02) in late-stage patients compared with either early-stage
disease or controls (Fig. 9A). We next assessed allostimulatory
function in patient-derived iMo-DC preparations (n $ 24) in com-
parison to normal donors (n $ 12) (Fig. 9B). In general, no sig-
nificant difference was observed in [3H]TdR uptake between nor-
mal DC vs patients’ DC. However, when the patients were
stratified by disease status, allostimulatory activity of iMo-DC
generated ex vivo from patients with locally advanced or meta-
static disease (n $ 10) was significantly lower than that of either
normal donors or of patients with earlier stages of cancer (n $ 14)
( p ) 0.001) (Fig. 9B). Since the responders were identical in each
series of the comparison, the difference in T cell proliferation de-
pended on the source of iMo-DC used. In addition, in iMo-DC
derived from advanced tumor patients, we also found a reduced
IL-12 p70 production upon CD40-L/IFN-#-stimulation ( p$ 0.02)
(Fig. 9C).
Alteration of balance between MDC and PDC in pancreatic
carcinoma patients
The two different subsets, MDC and PDC, with distinct biological
activities have been defined on the basis of their distinct pheno-
typic characteristics, LIN"HLA-DR!CD11c! and LIN"HLA-
DR!CD123! cells, respectively (32, 33). Immunophenotyping of
normal and cancer blood samples was performed by FACS anal-
ysis. Peripheral blood lymphocytes were stained with PerCP-anti-
HLA-DR mAb and FITC lineage mixture (R1) and HLA-DR!/
LIN" cells gated (R2). Within the R2 gate, we further analyzed the
expression of CD11c (R3) and CD123 (R4). Representative pro-
files of CD11c and CD123 expression by PB DC from a normal
subject are shown (Fig. 10A). The proportions of LIN"/HLA-
DR! cells were comparable ranging from 0.63 to 4.1 for healthy
FIGURE 7. Effects of pancreatic carcinoma-derived CM on IFN-# pro-
duction during allogeneic MLR (DC/T cells ratio 1:20). A, DC generated in
the presence of CM derived from PT-45, Capan-2, or BxPC-3 cells. B, DC
generated in the presence of CM derived from #1, #2, #3, and #4 cells. !,
p $ 0.01 vs DC generated in the absence of supernatants. All values are
expressed as mean & SD pg/ml of two sets of five (A) and three (B)
independent experiments. T cells alone produced constitutively 350 & 102
pg/ml. FIGURE 8. Effect of neutralizing Abs to IL-6, IL-10, and TGF-! on
iMo-DC allostimulatory function impaired by pancreatic carcinoma cell
line CM. The effects of anti-IL-6, -IL-10, and -TGF-! alone (A) or in
combination (B) are shown on MLR-induced T cell proliferation measured
in the absence (control) or presence of 20% CM derived from pancreatic
carcinoma cell lines. Results are expressed as mean & SD of [3H]TdR
uptake after 5 days of culture.
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individuals and from 0.67 to 3.9% for pancreatic carcinoma
patients.
The proportions of LIN"HLA-DR!CD11c! (myeloid origin)
or LIN"HLA-DR!CD123! (lymphoid origin) DC subsets were
normalized to the percentage of LIN"DR! DC precursors deter-
mined for each individual studied. As shown in Fig. 10B, a sig-
nificant difference in the relative proportions of CD11c! DC
within the LIN"DR! DC population was found in patients vs con-
trols (32.2 & 7.9 vs 44.2 & 6.7%, p $ 0.008). Additionally, the
percentage of MDC was found to be significantly different among
patients at different stages of tumor progression (advanced or met-
astatic cancer 27.7 & 3.1 vs early stage cancer 39.4 & 6.4, p $
0.013). By contrast, no significant differences in PDC subset fre-
quency were found between tumor patients and normal donors
(data not shown, p ' 0.05). Thus, when the data for MDC and
PDC subsets for each subject were combined to render the MDC:
PDC ratio, patients exhibited a significantly higher mean value
than those in normal controls ( p $ 0.03).
Discussion
This study demonstrates that pancreatic carcinoma cells produce
and secrete an array of cytokines that, in combination, suppress
DC survival and proliferation and induce a tolerogenic PDC-like
phenotype. Previous studies have focused on the effects of indi-
vidual tumor-derived or tumor-induced cytokines on DC function
as it relates to the immune response to malignant tumors (34). In
different tumor types, a host of DC regulatory cytokines has been
identified, which adversely affect the antitumor immune response;
these include VEGF, IL-10, TGF-!, and IL-6. Some of these are
produced by human tumor cells themselves, whereas others are not
only produced by tumor cells but also induced systemically by
tumor cell-derived products. For example, TGF-! produced by
human colonic carcinoma cells reduces the number of circulating
DC (35), and TGF-! produced by colorectal tumors in mice sup-
presses the efficacy of DC-based vaccination (36). By contrast,
IL-10 production by tumor cells appears to be amplified by induc-
tion of IL-10 production in host cells (37–39).
Although pancreatic carcinoma has been a popular target for
DC-based vaccine approaches (Refs. 40–42, for a review see Ref.
43), very little is presently known about causes and mechanisms
underlying the paucity of effective DC in those tumors (44, 45).
The present study establishes that pancreatic cancer cells in vitro
and in vivo express and produce an array of DC regulatory cyto-
kines in various combinations, including IL-10, TGF-!, IL-6, and
VEGF. Although the cellular sources of elevated cytokines in the
in vivo setting cannot be distinguished with certainty, our previous
findings (2, 3) and the present study lend support to the notion that
the tumor cells themselves contribute significantly to the intratu-
moral presence of theses cytokines and to elevated cytokine levels
in peripheral blood. Specifically, we observed previously that de-
bulking by surgical removal of primary pancreatic tumors resulted
in reduced levels of circulating TGF-! and IL-10 (3). Others have
described similar results consistent with a role of tumor-derived
secreted products in shaping the afferent arm of the systemic im-
mune response. Specifically, in prostate and breast cancers, DC
numbers recovered markedly upon surgical removal of the primary
tumor (46, 47).
Heretofore, most studies on the effects of tumor cells on DC
maturation and function have focused on single cytokines elabo-
rated by tumor cells. By contrast, the present study takes into ac-
count that different combinations of cytokines could have func-
tional consequences for DC maturation and function that are
potentially distinct from those caused by the individual cytokines.
For example, TGF-! has been reported to have multiple effects on
DC cells, including increased activation (48), protection against
apoptosis (49), differentiation into Langerhans cells, (50) and re-
distribution of DC cells from the circulation into the tumor bed
(34). By contrast, others have demonstrated that TGF-! impairs
the allostimulatory function of bone marrow-derived DC cells for
T cells (51) and inhibits the Ag-presenting and antitumor activities
of DC-based vaccines (36, 52). These observations highlight that
the same cytokine can have diverse and seemingly opposing effects
on DC maturation and function in different experimental circum-
stances possibly due to microenvironmental cues and the presence
of other cytokines. The finding that pancreatic carcinoma cells
elaborate at least four DC-modulatory cytokines (this study) raises
the question of the net effect of these tumor-derived products on
DC maturation and function.
The results of our investigation support the conclusion that the
combined effects of pancreatic carcinoma-associated cytokines
lead to the development of a predominant tolerogenic PDC-like
Table IV. Immunophenotype of Mo-DC from normal donors generated in the absence or presence of pancreatic carcinoma cell line CM and effects
of IL-6, IL-10, TGF-!, and VEGF-neutralizing Abs
Surface
Markers
iMo-DC
Control PT-45 Capan-2 BxPC-3 Control PT-45 Capan-2 BxPC-3
Mixture of neutralizing Abs
CD14 1 & 0.6a 10 & 4 8& 1.3 12& 4 1.1& 0.8 7 & 2 5.6 & 1.4 7 & 5
CD1a 44 & 7 42.4 & 13 29 & 9 31& 9 46.7& 8 41.4& 4 36 & 9 46.4& 5
CD40 64.7 & 20 50.5 & 7. 39.1& 7 41 & 3 63.7& 6 64 & 6 58& 5 55& 8
p $ 0.02b p $ 0.004 p $ 0.04
(231 & 97)c (210 & 59) (196& 45) (201& 77) (250& 65) (235& 78) (262& 87) (254& 76)
p $ 0.04 p$ 0.03 p$ 0.015
CD80 4.5 & 2 8.4 & 4 6 & 2 4.5 3.9 & 1 5.6& 2 6 & 1 7& 3
CD83 48 & 13.5 32 & 4 21& 5 27.2& 5 41.9& 6 45.8& 10 38 & 7 34& 5
CD86 23 & 7 14 & 8 18.5& 3 12 & 2 23.6& 2 17.9& 3 21 & 3 24.4& 4
HLA-DR 83.3& 15 44.5 & 12 29.2& 3 35.7& 5 91 & 8 75.8& 2 85 & 12 84& 10
p $ 0.04 p$ 0.02 p$ 0.006
(503 & 123) (357& 87) (154& 98) (250& 67) (593& 99) (663& 123) (545& 92) (587& 101)
p $ 0.005 p$ )0.001 p $ 0.003
a Value are expressed as mean percentage positive cells & SD of four separate experiments.
b Value of p vs control.
c Value are expressed as MFI & SD of four separate experiments. Only statistically significant MFI differences are included.
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phenotype, characterized by low expression levels of costimula-
tory molecules and poor T cell stimulatory capacity and low levels
of IL-12 production. Among the four cytokines tested, IL-10 and
TGF-! appeared to be most important for reduced T cell stimula-
tory function, as determined by MLR, whereas IL-6 appeared to
have a minor role, and tumor-derived VEGF made no discernible
contribution, at least in the in vitro setting.
Furthermore, in advanced stages of pancreatic tumor develop-
ment, tumor-derived secreted products induce a systemic MDC/
PDC imbalance in the host. This result is consistent with other
reports in different tumor systems. For example, in squamous cell
carcinomas of the head and neck, markedly lower numbers of cir-
culating DC with MDC characteristics have been observed (46).
Similar results have been reported in early breast cancer, which is
characterized by significant decreases in MDC (47). Of note, we
FIGURE 9. iMo-DC function in pancreatic carcinoma patients. A, Phe-
notype of iMo-DC generated ex vivo from pancreatic carcinoma patients vs
normal iMo-DC. Values are expressed as mean percentage positive cells&
SD. !, p $ 0.02 and values determined comparing iMo-DC generated from
pancreatic carcinoma patients vs control iMo-DC. B, Allostimulatory func-
tion of iMo-DC generated from pancreatic carcinoma patients vs control
iMo-DC. Results are expressed as mean & SD of [3H]TdR uptake after 5
days of MLR culture in triplicate. !!!, p ) 0.001 vs control DC. C, IL-
12p70 secretion by CD40L- and IFN-#-stimulated Mo-DC from pancreatic
carcinoma patients vs control Mo-DC. Results are shown as the mean &
SD pg/ml. !, p $ 0.02 vs control DC.
FIGURE 10. Depletion of CD11c!,CD123" DC in patients with pan-
creatic carcinoma. A, Gating strategy for identification of dendritic sub-
types in PB of a representative healthy control by four-color, rare-event,
flow cytometric analysis. Mononuclear cells were first gated out according
to the forward and sideward scatter (R1). Gated on the mononuclear cell
analysis region (R1), DC were identified on the basis of their lack of la-
beling for the FITC-conjugated lineage markers containing anti-CD3,
-CD14, -CD16, -CD19, -CD20, and -CD56 (R2). Lineage-negative cells
were analyzed for the coexpression of HLA-DR (Per-Cp conjugated) and
CD11c (PE-conjugated) (R3) or CD123 (PE-conjugated) (R4). B, The in-
cidence of MDC (CD11c!,CD123") subset was expressed as a percentage
of LIN"HLA-DR! PBMC. C, Ratios of PDC (LIN"HLA-DR!, CD123!)
to MDC (lineage", HLA-DR!, CD11c!). Values represent means & SD.
Significant differences between patient groups and healthy donors are
shown.
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observed measurable alterations in MDC only in advanced-stage
pancreatic carcinoma patients but not in early-stage disease. In
addition to the tumor-derived cytokines described here, regulatory
T cells (CD4!,CD25!) and/or suppressor macrophages present in
DC preparations may contribute to the PDC-like phenotype. How-
ever, we consider this possibility unlikely because the DC popu-
lations under study were 95–97% pure.
In conclusion, this study shows that, in advanced pancreatic car-
cinoma, tumor-derived cytokines profoundly affect the phenotype
and function of DC in favor of a tolerogenic DC2 phenotype.
Among the cytokines produced by pancreatic carcinoma cells,
IL-10 and TGF-! appear to be most important for this effect. These
are the same cytokines previously found to tilt the T cell response
in pancreatic tumor patients toward a less effective Th2 phenotype
(3, 53). These results are consistent with the notion that the efficacy
of DC-based vaccines may be limited by the local and systemic
tumor-induced cytokine milieu in tumor patients. Thus, it may be
beneficial to neutralize IL-10 and/or TGF-! during immunization
of pancreatic tumor patients with DC.
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